Coronavirus (COVID-19)
Learn more
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors
Eligibility Criteria:
Part I (dose escalation):
--Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours (any type)
Part II (dose expansion):
This study is for patients age 18 and older.
Available at: Hartford Hospital and Hospital of Central Connecticut
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209